Latest project updates
Oncode Institute aims to outsmart cancer and impact lives. To achieve this, Oncode focuses on three pillars: excellent research, intensive collaboration and powerful valorization. The research strategy is focused on understanding the basic mechanisms of cancer to realize the ultimate goal: safer and more effective medical solutions as well as personalized precision diagnostics. Oncode brings together excellent cancer researchers in The Netherlands: 61 research groups from 12 different Dutch research institutes collaborate on 6 interdisciplinary research themes. To speed up the translation of scientific discoveries into clinical applications, Oncode has a dedicated team of specialists to support scientists in the valorization process.
12 partner institutions
61 Principal Investigators
€ 120 million
funding for 5 years
About Oncode Institute
Over the past decades, the scientific and medical community has made tremendous progress in understanding and treating cancer. However, the disease still has a large burden on society as cancer has become the primary cause of death in The Netherlands. In an effort to address this unmet clinical need, Dutch cancer researchers have joined forces within Oncode Institute. To come up with new avenues for treatment and diagnosis, Oncode focuses on better understanding the fundamental mechanisms of cancer biology. With the ultimate goal to improve long-term survival and the quality of life of patients.Oncode serves as a platform for excellent cancer researchers in The Netherlands to collaborate, share knowledge, expertise and technology. As a virtual Institute it stimulates scientific freedom and offers dedicated support to optimize the translation of fundamental insights into clinical applications. Outsmarting cancer, impacting lives. Visit the Oncode website for more information about the project.
Over 800+ Oncode researchers working under a single strategy that focuses on six different research themes:
- Development of novel technologies
- Understanding the critical drivers of tumour growth and the causes of resistance
- Analysis of network perturbations in tumours and tumour-host interactions
- Causes and consequences of genetic instability
- Identification of critical drug combinations and biomarkers for personalized cancer treatments
- Mobilising immune defence
Oncode invests heavily in the transfer of results from fundamental research into clinical applications. A team of dedicated specialists will help Oncode researchers with valorization of their findings. Furthermore, Oncode offers tailored training programs for affiliated researchers and actively invests in diversity through its Young Female Investigator program.
Accelerating innovation by partnership management
Based on its broad experience with partnership management and communication, Lygature has become a partner of Oncode. Lygature supports Oncode Institute with the following services:
- Program management
- Communication & external affairs
- Finance & IT-infrastructure
- Patient engagement
Lygature together with
Project updates
-
Follow-up funding for Oncode Institute to keep cracking the code of cancer
Oncode Institute is a virtual fundamental cancer research institute aiming to accelerate breakthrough discoveries and speed up their translation into new diagnostics and treatments for cancer patients. With over 110 patents filed, a wide range of unique collaborations between scientists, clinicians and industry partners, 9 oncology start-ups, 1.681 published papers and 16 studies in the clinical proof of concept phase, Oncode has proven over the past 5 years that its unique approach works. KWF, the Top Sector Life Sciences & Health, ZonMw and the ministries of EZK, VWS and OCW invest 92 million euros so Oncode can continue its mission to outsmart cancer and impact patients’ lives.
-
Oncode’s first live Patient Engagement event brings researchers and (ex) patients closer together
Highlights of Oncode's first Patient Perspective meeting, where patient partners had the opportunity to talk with researchers, discuss their ideas and visit multiple labs at The Netherlands Cancer Institute.
-
License signed: Oncode successfully mediates agreement for innovative algorithm RAINFOREST
Oncode’s valorization team at work: we are happy to announce that SkylineDx has signed a license agreement with Oncode Institute and Utrecht Holdings on a shared patent covering the innovative algorithm RAINFOREST.
The algorithm is the work of Oncode Investigator Jeroen de Ridder in collaboration with Joske Ubels, who, when the project started in 2019 was a PhD student in de Ridder’s lab and a Skyline employee. Oncode then, in collaboration with Utrecht Holdings, put in place the agreement to grant Skyline the option to acquire the IP - which they exercised - and then worked to put the license in place.